menopause

SNRI may be as effective as estrogen for hot flashesA small study led by investigators from Brigham and Women’s Hospital suggests that the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine hydrochloride may be as effective as low-dose estradiol for relief of hot flashes.
Early menopause tied to heart failureAccording to a recent study in Menopause, women who go through natural menopause at ages 40 to 45 may be at increased risk of developing heart failure and smoking may produce a similar risk among those who experience menopause at ages 46 to 49.
Premature menopause associated with risk of lower cognitive functionEarly menopause—whether natural or surgical—may be associated with negative effects on cognitive function that are not entirely offset by postmenopausal hormone therapy (HT), according to a new study in BJOG.
Heavy or prolonged bleeding in menopause is not uncommon
Heavy or prolonged bleeding in menopause is not uncommonWomen undergoing the menopausal transition may be prone to prolonged bleeding with periods of heaviness, according to a new study in BJOG.
‘9 Foods That Fight Hot Flashes’A study from The American Journal of Clinical Nutrition is the basis for this article in Woman's Day. A link to the North American Menopause Society’s website is offered in the introduction, but not one to the study abstract itself.
A little exercise better than none for overweight postmenopausal women
A little exercise better than none for overweight postmenopausal womenWomen should not feel that they need to log long hours of vigorous exercise to see any benefits, says a study from Spain.
FDA approves drug for postmenopausal symptomsThe first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
New molecular entityOn February 26, 2013, FDA approved ospemifene (Osphena, Shionogi Inc.) for the treatment of moderate-to-severe dyspareunia resulting from vulvar and vaginal atrophy associated with menopause. Estrogen levels decline during menopause, resulting in a thinning and drying of vaginal tissues. This atrophy can cause a woman to experience pain during intercourse (dyspareunia).
NAMS updates recommendations for vulvovaginal atrophyEstrogen therapy is still the mainstay of therapy for moderate-to-severe symptoms and long-term studies on endometrial safety of local estrogen and ospemifene are lacking. Those are the key conclusions from an updated position statement on management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women issued by the North American Menopause Society (NAMS).
FDA approves first nonhormonal treatment for hot flashesFDA has approved low-dose paroxetine capsules (Brisdelle, Noven Pharmaceuticals), 7.5 mg/day, for treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, also referred to as hot flashes and night sweats.